Strand Life Sciences, a subsidiary of Reliance Industries Limited, announced the launch of its Somatic Advantage 74 Liquid Biopsy (SA74 LB) Test on Friday. This test is designed to detect circulating tumor DNA in the blood samples of cancer patients, offering a detailed analysis of 74 clinically significant genes and providing crucial information for cancer treatment decisions.
As reported by financialexpress.com, building on 24 years of expertise and over 50,000 genetic tests performed, Strand Life Sciences has developed the SA74 LB Test to deliver exceptional accuracy and sensitivity. The test employs Unique Molecular Identifiers (UMIs) to ensure the precise detection of genetic variants, making it a reliable tool for identifying potential biomarkers and guiding treatment choices. The company’s CAP and NABL-accredited lab upholds stringent quality standards, adhering to international best practices.
Key features of the SA74 LB Test include:
- Actionable Insights: Covers genomic alterations in 74 clinically significant genes linked to therapy selection for solid tumors, as recommended by FDA and NCCN guidelines.
- High Reliability: Utilizes UMI-based library preparation, achieving high analytical sensitivity.
- Deep Coverage: Ensures pre-UMI coverage of over 15,000x and post-UMI coverage of over 2,000x, providing enhanced sensitivity and a thorough analysis of genetic alterations.
- Minimally Invasive: Requires only a peripheral blood sample, making it a more comfortable and convenient option for patients.
According to the company, the SA74 LB Test offers several benefits over traditional tissue biopsies. Its minimally invasive nature and capability to capture genetic variability from multiple tumor sites make it an invaluable tool for clinicians and patients, especially when tumors are not accessible or tissue samples are insufficient or of poor quality. By providing timely and accurate information, the SA74 LB Test helps optimize treatment plans and improve patient outcomes.
“We are excited to expand our Somatic Advantage portfolio with the introduction of the SA74-LB Test,” said Dr. Ramesh Hariharan, CEO of Strand Life Sciences. “This actionable liquid biopsy test aims to make genetic testing more accessible and beneficial for patients. Strand Life Sciences is dedicated to driving innovation in precision medicine and equipping healthcare professionals with the tools needed to provide personalized care. The launch of the SA74 LB Test reflects our commitment to advancing cancer diagnostics and enhancing patient lives.”